Comparative In Vitro Evaluation of BL-P1654 and Carbenicillin Against Pseudomonas | Zendy

Gary D. Overturf | Zendy; R. Ressler | Zendy; J. Wilkins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative In Vitro Evaluation of BL-P1654 and Carbenicillin Against Pseudomonas

Author(s) -

Gary D. Overturf,

R. Ressler,

J. Wilkins

Publication year - 1974

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.6.5.643

Subject(s) - carbenicillin , pseudomonas , microbiology and biotechnology , minimum inhibitory concentration , pseudomonas aeruginosa , penicillin , in vitro , antibacterial activity , enterobacteriaceae , antibiotics , chemistry , biology , ampicillin , bacteria , escherichia coli , biochemistry , genetics , gene

Prior investigators have reported a broad gram-negative spectrum and a marked anti-Pseudomonas activity in vitro with BL-P1654, 6-[R-alpha-(guanylureido)phenylacetamido]-penicillanic acid. An in vitro comparison of BL-P1654 to carbenicillin was performed against 84 strains of Pseudomonas and 39 strains of Enterobacteriaceae. Mean minimal inhibitory concentrations in Mueller-Hinton broth of BL-P1654 and carbenicillin were 12.5 and 100 mug/ml, respectively. Bactericidal studies with representative strains of Pseudomonas showed a consistent lack of bactericidal activity with BL-P1654. Mean bactericidal concentrations of BL-P1654 and carbenicillin were >/=200 and 100 mug/ml, respectively. The lack of bactericidal activity of BL-P1654 was further substantiated with the "killing curve" technique. Based on these data, BL-P1654 can not be considered a substitute for carbenicillin as the penicillin analogue of choice for Pseudomonas infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research